Manufacturer and Field-Facing Advisory

Medical affairs advisory for manufacturers and field-facing teams

Provider-side reimbursement and coverage education, oncology pathway and protocol review, and peer-level scientific exchange support for oncology pharmacy and infusion teams. Non-promotional, clinically grounded, and written for the audience that actually sits on the committee.

What this covers

Advisory and educational work only. Every engagement is documented, non-promotional, and product-neutral.

Provider-side reimbursement and coverage education

How coverage, coding, and site of care actually work inside a health system, taught to the teams who have to discuss it accurately in the field.

  • Coding, billing, and claim mechanics for provider-administered therapy
  • Buy-and-bill versus specialty pharmacy dynamics
  • Payer policy navigation and medical policy review
  • Site-of-care and benefit routing implications

Formulary and P&T committee strategy

What evidence and dossiers health-system pharmacy leaders actually need, and what gets a package sent back.

  • How health-system P&T committees are structured and sequenced
  • Evidence expectations, dossier format, and pre-read standards
  • Budget impact and total cost of care questions committees ask
  • Common reasons a submission stalls

Oncology pathway and protocol review

The distance between a label and an order set, and what closes it.

  • Pathway and regimen library implications
  • Protocol, order set, and build considerations
  • Clinical-to-operational implementation support
  • Infusion capacity, chair time, and scheduling impact

Scientific exchange and peer-level education

Education delivered pharmacist to pharmacist, at the level the audience works at.

  • Peer-level education for oncology pharmacy and infusion teams
  • Advisory board and roundtable participation
  • Preparation support for field medical and reimbursement teams
  • Institutional workflow and decision-process briefings

Voice of the customer

An accurate read on institutional access barriers from someone who sat on the institutional side.

  • Institutional access barrier assessment
  • Provider and pharmacy perspective on program design
  • Hub, copay, and access program friction from the clinic side
  • Validation input on field and access program assumptions

Field team enablement

What field medical, medical science liaison, and field reimbursement teams need to be credible in a pharmacy director's office.

  • What pharmacy leadership is measured on and what it will not discuss
  • How institutional purchasing, 340B, and inventory actually interact
  • Framing an access conversation without a promotional claim
  • Common missteps that end a meeting early

How this work is structured

All manufacturer-facing work is non-promotional and product-neutral. I do not make claims about specific products, do not participate in promotional speaker programs, and do not provide off-label promotion of any kind. Engagements are documented under a written scope with fair-market-value compensation and are structured to be consistent with your compliance requirements. Any conflict of interest is disclosed in writing before work begins.

What you get

Deliverables are short by design. The test is whether your team can run them after I leave.

Deliverables

  • Written, non-promotional education material scoped to your audience
  • Session or workshop delivery for field, medical, and access teams
  • A structured institutional perspective summary from advisory work
  • Follow-up briefing documents your team can reuse internally

When people call

  • A field or medical team needs accurate provider-side reimbursement grounding
  • A launch is approaching and the institutional access pathway is not well understood
  • Dossiers and evidence packages are not landing with health-system committees
  • You want provider-side input on an access or hub program before it scales
  • An advisory board needs a health-system pharmacy leadership perspective

Start with a 30-minute call

Bring the audit finding, the number that is not adding up, or the workflow that keeps stalling. If I can help I will tell you how. If I cannot, I will point you to someone who can.